{
    "clinical_study": {
        "@rank": "50397", 
        "arm_group": [
            {
                "arm_group_label": "Sequence 1", 
                "arm_group_type": "Experimental", 
                "description": "Participants will self administer 1 spray of esketamine solution to each nostril using a intranasal (through nose) device with a nasal guide on Day 1 of period 1 as treatment regimen A at time 0 and repeated twice every 5 minutes (total dose: 84 mg). There will be a washout period of 5-10 days between the treatment regimens. On Day 1 of period 2, participants will self administer 1 spray of esketamine solution to each nostril using a intranasal device without a nasal guide as treatment regimen B at time 0 and repeated twice every 5 minutes (total dose: 84 mg)."
            }, 
            {
                "arm_group_label": "Sequence 2", 
                "arm_group_type": "Experimental", 
                "description": "Participants will self administer 1 spray of esketamine solution to each nostril using a intranasal device without a nasal guide on Day 1 of period 1 as treatment regimen B at time 0 and repeated twice every 5 minutes (total dose: 84 mg). There will be a washout period of 5-10 days between the treatment regimens. On Day 1 of period 2, participants will self administer 1 spray of esketamine solution to each nostril using a intranasal device with a nasal guide as treatment regimen A at time 0 and repeated twice every 5 minutes (total dose: 84 mg)."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary purpose of the study is to evaluate the pharmacokinetics (what the body does to\n      the medication) of intranasally (through the nose) administered esketamine using a device\n      with and without a nasal guide in healthy participants."
        }, 
        "brief_title": "A Study to Evaluate the Pharmacokinetics of Intranasal Esketamine Administered With and Without a Nasal Guide on the Intranasal Device", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This is a randomized (the study medication is assigned by chance), single-center,\n      single-dose, 2-way crossover (participants may receive different interventions sequentially\n      during the study in 2 sequence groups), open-label (all people know the identity of the\n      intervention) study. Approximately, 14 participants will be enrolled in this study. This\n      study will consist of a screening phase of up to 21 days, a treatment phase of 3 days, and a\n      follow-up phase of 9-13 days. Participants will be randomly allocated to 1 of the 2\n      treatment groups (Sequence 1 and 2). In sequence 1, participants will self-administer\n      esketamine intranasally using a device with nasal guide as treatment A on Day 1 of period 1\n      and intranasally esketamine using a device without nasal guide as treatment B on Day 1 of\n      period 2. In sequence 2, participants will self-administer intranasally esketamine as\n      treatment B on Day 1 of period 1 and intranasally esketamine as treatment A on Day 1 of\n      period 2. There will be a washout period of 5 to 10 days between each treatment regimen.\n      Safety evaluations will include assessment of adverse events, clinical laboratory tests,\n      electrocardiogram, vital signs, physical examination, pulse oximetry, targeted nasal\n      examination, nasal device questionnaire, and in addition to these evaluations, specific\n      scales will be used to assess the safety. The study duration for each participant will be\n      approximately 45 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Agrees to protocol-defined use of effective contraception\n\n          -  If a woman, must have a negative serum human chorionic gonadotropin (hCG) pregnancy\n             test at screening; and a negative urine pregnancy test on Day -1 of each treatment\n             period\n\n          -  Body mass index (BMI) (weight [kg]/height2 [m]2) between 18 and 30 kg/m2 (inclusive),\n             and body weight not less than 50 kg\n\n          -  Blood pressure (after the participant is supine for 5 minutes) between 90 and 140\n             mmHg systolic, inclusive, and no higher than 90 mmHg diastolic\n\n          -  A 12-lead electrocardiogram (ECG) consistent with normal cardiac conduction and\n             function\n\n        Exclusion Criteria:\n\n          -  Current or prior history of psychiatric disorder including but not limited to\n             psychotic, bipolar, major depressive, or anxiety disorder\n\n          -  Clinically significant medical illness including cardiac arrhythmias or other cardiac\n             disease, hematologic disease, coagulation disorders , lipid abnormalities,\n             significant pulmonary disease, including bronchospastic respiratory disease, diabetes\n             mellitus, renal or hepatic insufficiency, thyroid disease, neurologic disease,\n             infection, hypertension or vascular disorders, kidney or urinary tract disturbances,\n             sleep apnea, myasthenia gravis, or any other illness\n\n          -  Clinically significant abnormal values for hematology, clinical chemistry, or\n             urinalysis at screening or at admission to the study center (Day -1) as deemed\n             appropriate by the investigator\n\n          -  Clinically significant abnormal physical examination, vital signs, or 12-lead ECG at\n             screening or at admission to the study center (Day -1 of each treatment period) as\n             deemed appropriate by the investigator\n\n          -  Has an abnormal or deviated nasal septum with any 1 or more of the following\n             symptoms: blockage of 1 or both nostrils, nasal congestion (especially 1-sided),\n             frequent nosebleeds, frequent sinus infections, noisy breathing during sleep, facial\n             pain, headaches, and postnasal drip"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02060929", 
            "org_study_id": "CR102971", 
            "secondary_id": "ESKETINTRD1004"
        }, 
        "intervention": {
            "arm_group_label": [
                "Sequence 1", 
                "Sequence 2"
            ], 
            "description": "Participants will self administer 1 spray of esketamine solution using a intranasal device with a nasal guide in Treatment A regimen and without nasal guide inTreatment B regimen at time 0 and repeated twice every 5 minutes (total dose: 84 mg).", 
            "intervention_name": "Esketamine", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Healthy", 
            "Esketamine", 
            "Intranasal", 
            "Nasal Guide", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "March 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Merksem", 
                    "country": "Belgium"
                }
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-Label Phase 1 Study to Evaluate the Pharmacokinetics of Intranasal Esketamine Administered With and Without a Nasal Guide on the Intranasal Device", 
        "overall_official": {
            "affiliation": "Janssen Research & Development, LLC", 
            "last_name": "Janssen Research & Development, LLC Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Cmax is defined as maximum observed analyte concentration.", 
                "measure": "Maximum Observed Plasma Concentration (Cmax) of Esketamine", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, and post-dose 7, 12, 22, 32, 40, 50 minutes, 1, 1.25, 1.5, 2, 3, 4, 24 hours"
            }, 
            {
                "description": "Tmax is defined as actual sampling time to reach maximum observed analyte concentration.", 
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax) of Esketamine", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, and post-dose 7, 12, 22, 32, 40, 50 minutes, 1, 1.25, 1.5, 2, 3, 4, 24 hours"
            }, 
            {
                "description": "The AUClast is area under the plasma concentration-time curve from time zero to the last quantifiable concentration.", 
                "measure": "Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUClast) of Esketamine", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, and post-dose 7, 12, 22, 32, 40, 50 minutes, 1, 1.25, 1.5, 2, 3, 4, 24 hours"
            }, 
            {
                "description": "The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of Area under Curve (AUC) last and C(last)/lambda(z), in which C(last) is the last observed quantifiable concentration", 
                "measure": "Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of Esketamine", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, and post-dose 7, 12, 22, 32, 40, 50 minutes, 1, 1.25, 1.5, 2, 3, 4, 24 hours"
            }, 
            {
                "description": "T1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal rate-constant (lambda[z]) of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).", 
                "measure": "Elimination Half-Life Period (T1/2) of Esketamine", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, and post-dose 7, 12, 22, 32, 40, 50 minutes, 1, 1.25, 1.5, 2, 3, 4, 24 hours"
            }, 
            {
                "description": "First-order rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve.", 
                "measure": "First-order Rate Constant of Esketamine", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, and post-dose 7, 12, 22, 32, 40, 50 minutes, 1, 1.25, 1.5, 2, 3, 4, 24 hours"
            }, 
            {
                "description": "Relative bioavailability is the percentage of the administered dose that is systemically available.", 
                "measure": "Relative Bioavailability (Frel) of Esketamine", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, and post-dose 7, 12, 22, 32, 40, 50 minutes, 1, 1.25, 1.5, 2, 3, 4, 24 hours"
            }, 
            {
                "description": "The CADSS is a clinician administered rating scale designed to measure dissociative symptoms. The CADSS comprises 23 subjective items, divided into 3 components: depersonalization, derealization and amnesia. Participant's responses are coded on a 5-point scale (0 = \"Not at all\" through to 4 = \"Extremely). Higher scores indicate worsening.", 
                "measure": "Change From Baseline in Clinician-Administered Dissociative States Scale (CADSS) Score", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline (Day -1) and Day 2"
            }, 
            {
                "description": "The BPRS is used for the measurement of psychiatric symptoms. The BPRS is an 18 item questionnaire and each question is rated on a 7-point scale ranging from 1 (not present) to 7 (extremely severe). The total score for the 18 question will be calculated by adding score of each question. The interpretation of the total scores are: 0-9 will indicate \"not a schizoaffective case\"; 10-20 will indicate \"possible schizoaffective case\"; and 21 or more, will indicate \"evident schizoaffective case\". Higher scores indicate worsening.", 
                "measure": "Change From Baseline in Brief Psychiatric Rating Scale (BPRS) Score", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline (Day -1) and Day 2"
            }, 
            {
                "description": "The MOAA/S is a 6-point ordinal scale measuring a patient's level of sedation. Scores range from 0 (No response to painful stimulus [trapezius squeeze]) to 5 (Responds readily to name spoken in normal tone [awake]). MOAA/S scores were classified as 0-1, 2-4 and 5.", 
                "measure": "Change From Baseline in Modified Observers Assessment of Alertness/Sedation (MOAA/S) Score", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline (Day 1) and Day 2"
            }, 
            {
                "description": "The C-SSRS is a clinical interview to assess severity and track suicidal events providing a summary of both suicidal ideation and behavior to identify the level and type of suicidality present.", 
                "measure": "Change From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) Score", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline (Screening - Day -21 to Day -2) and follow-up visit (11 to 13 days after final dose)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02060929"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Janssen Research & Development, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Research & Development, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}